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Abstract
Variants of the S49 mouse lymphoma cell line exhibit multiple lesions along the pathway of cyclic AMP generation in
response to b -adrenergic stimulation. Two such variants, b p and b d, are characterized by decreased receptor binding and2
mRNA expression, 50% and 25% of wild-type receptor expression, respectively. The rate of b -adrenergic receptor2
synthesis was measured and found to be decreased in the bd cells vis-a-vis the rate in wild type cells. The molecular mass`
of the b -adrenergic receptor in the S49 wild-type, b p and b d variant cells was estimated by labeling the receptor with the2
w125 xphotoaffinity probe I iodocyanopindololdiazirine. Receptor size was found to be 67 000 and 47 000 Da in the wild-type
and 60 000 and 42 000 in the two variant cells. This 6 kDa discrepancy in mass was abolished upon treatment of labeled cell
extracts with N-glycosidase F, suggesting the possibility of either N-terminal truncation or altered glycosylation of the
receptor in the variant cells. To distinguish between these possibilities, we sequenced the b -adrenergic receptor gene and2
two kilobases of the 5X-non-coding region. No differences were found in the coding region of the gene from wild-type, b p
and b d S49 cells suggesting that both the diminished expression and the decreased size of b -adrenergic receptor in the b p2
and b d S49 variants are related to impaired glycosylation of the receptor. This hypothesis was substantiated by the reduced
retention of the variant cells’ b -adrenergic receptor on immobilized WGA. Furthermore, growth of the S49 cells in the2
presence of the a-mannosidase II inhibitor, swainsonine, preferentially impaired the ability of the receptors derived from the
variant cells to bind to WGA. These results imply that altered expression and glycosylation of G-protein-linked receptors
occur as a consequence of one or more mutations outside the receptor’s open reading frame. q1997 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The b -adrenergic receptor gene has been cloned2
w xfrom several species 1–3 . In each, it is encoded by a
single intronless gene, 1.3 kb in length. Transcrip-
tion-regulating elements are located upstream of the
w xopen reading frame 2,4 . The receptor contains seven
clusters of hydrophobic amino acids, each cluster
being of sufficient size to span the plasma membrane.
w xBy homology with bacterial rhodopsin 5 , these clus-
ters are postulated to span the membrane. The N-
terminal of the b -adrenergic receptor contains two2
consensus sequences, Asn-X-Ser, for N-glycosylation
w x6,7 . That such glycosylation actually occurs has
w xbeen suggested by experiment 8–11 . The core
polypeptide has a molecular weight of some 47 000
Da. The C-terminal of the receptor contains consen-
sus sequences for phosphorylation by both b-adren-
 1.ergic receptor kinase bARK , on Ser and Thr
residues, and by cyclic AMP-dependent protein ki-
 . w xnase PKA , on the Arg-Arg-Ser-Ser motif 12 .
The b -adrenergic receptor, like many other hor-2
w xmone receptors, is dynamically regulated 13 . Regu-
lation of responsiveness to b -adrenergic agonists2
occurs at many levels, from gene transcription to
regulation of the receptor at the cell surface and
w xcoupling to the G protein 14,15 .s
The S49 murine T lymphoma cell line, along with
variants that lack critical functions necessary for hor-
monal stimulation of cellular response, has provided
much insight into the mechanism by which b -adren-2
ergic receptors activate adenylyl cyclase via Gs
w x16,17 . The S49 cell has played a seminal role in
furthering research into the adrenergic-responsive
adenylyl cyclase system due to the isolation of multi-
ple variants along the pathway of cyclic AMP genera-
tion and response. Two such S49 variants, b p and
b d, were initially characterized as expressing de-
w xcreased numbers of b -adrenergic receptors 18 . The2
b p variant expresses approx. 50% and the b d vari-
ant expresses approx. 25% of the wild-type comple-
w xment of b -adrenergic receptors 18 . This decrease2
in cell surface b -adrenergic receptor expression has2
been established by us to correspond to decreased
receptor-specific mRNA expression in these variant
w xcells 19 .
In the current studies, we have investigated addi-
tional biochemical properties of the b -adrenergic2
receptor in S49 wild-type, b p and b d variant cells,
including determination of the primary sequence of
the receptor gene from the S49 wild type, b p and b d
variant cells. We have documented that receptors are
synthesized more slowly in the bd variant cells than
in the wild type S49 cells and, using photoaffinity
labeling, we have been able to demonstrate a de-
crease in the molecular mass of the b -adrenergic2
receptor in the b p and b d variant cells. This differ-
ence in mass disappears upon treatment of the labeled
cell membranes with N-glycosidase F glycopepti-
.dase F , suggesting either truncation of the N-terminus
of the b -adrenergic receptor in the variant cells,2
mutation andror impaired glycosylation at the glyco-
sylation motifs. By sequencing the b -adrenergic re-2
ceptor gene plus an additional two kilobases of the 5X
non-coding region from the S49 wild-type, b p and
b d variant cells we are able to demonstrate that
neither of the first two possibilities occurs. Therefore,
one or more mutations in other than the receptor
coding sequence must be responsible both for the




 . w 125 x  .y - I iodocyanopindolo l and y -
w125 xI iodocyanopindololdiazirine was purchased from
 . w125 xDuPont NEN and y - I iodocyanopindo-
loldiazirine from Amersham. BIM was a generous
gift from Dr. Josef Pitha National Institute of Aging,
.Baltimore, MD . Sequenase II dideoxy sequencing kit
was purchased from United States and GELase from
Epicenter Technologies. NuSieveGTG low melting
temperature agarose was purchased from FMC Bio-
Products. XL1-Blue MRF’ competent bacteria and
other enzymes, including Pfu polymerase, were pur-
chased from Stratagene Cloning Systems. X-Omat
AR film was purchased from Kodak and the UV
 .irradiation chamber from CBS Scientific. " -Pro-
pranolol was a gift from Ayerst, New York. Endogly-
cosidase H and N-glycosidase F were purchased
from Boehringer Mannheim, swainsonine from Cal-
biochem, N-acetyl-D-glucosamine from Fluka and
 .immobilized wheat germ agglutinin WGA from EY
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Laboratories. Oligonucleotides were purchased from
Genosys and all other chemicals from Sigma.
2.2. Cell culture
S49 wild type, b p and b d cells were grown in
 .Dulbecco’s modified Eagle’s DME medium supple-
mented with 10% horse serum in a 378C incubator in
10% CO in air. For some experiments, swainsonine2
 .0.2 mgrml was added to the growth medium three
days prior to harvesting the cells.
2.3. Photoaffinity labeling of receptors
S49 cells were harvested and washed twice in
phosphate-buffered saline prior to resuspension in
Dulbecco’s modified Eagle’s medium supplemented
 .with 0.1% wrv bovine serum albumin and 20 mM
Hepes, pH 7.4. Approx. 5P107 cells were incubated
 .in a vol of 1 ml together with 100 pM y -
w125 xI iodocyanopindololdiazirine and 10 mM phento-
 .lamine to reduce non-specific binding in the pres-
ence or absence of 1 mM propranolol to define
.non-specific binding for 45 minutes at 378C in a
shaking water bath. The cells were diluted with 5 ml
ice-cold buffer 137 mM NaCl, 5.4 mM KCl, 1.1 mM
.KH PO , 1.1 mM Na PO , pH 7.2 , washed at 48C2 4 2 4
and resuspended in 2 ml of this buffer. Each batch of
resuspended cells was placed in one of the 3.5 cm
diameter wells of a 6 well culture plate and the plate
was subjected to UV-irradiation for 10 min on ice.
The cells were washed twice more in ice-cold buffer
150 mM NaCl, 20 mM Hepes, 5 mM EDTA, pH
.7.4 and subjected to N cavitation in a Parr bomb.2
The disrupted cells were centrifuged at 200=g to
remove any intact cells and nuclei. The supernatant
was then centrifuged at 35 000=g. The membrane
pellet was resuspended into 0.3 ml water using a 1 ml
syringe and a 22-guage needle. The protein concen-
tration was measured and adjusted to 1.25 mgrml.
Glycosidase treatment was performed on these mem-
w xbrane preparations as described previously 20 .
Membranes were incubated with 33 Urml N-glyco-
sidase F for 16 h at 37qC in 100 mM sodium phos-
phate, pH 6.1, 50 mM EDTA, 200 mM NaCl, 1%
 .  .wrv digitonin, 1% vrv Nonidet P-40, 0.1% SDS,
10 mgrml leupeptin, 5 mgrml pepstatin A and
 .0.01% wrv phenylmethylsulfonylfluoride or with
33 Urml endoglycosidase H for 16 h at 378C in the
same buffer except that 11 mM sodium citrate pH 5.5
replaced sodium phosphate. One fifth volume of sam-
ple loading buffer 375 mM Tris-HCl, 3.6 mM b-
.mercaptoethanol, 50% glycerol, 15% SDS, pH 6.8
was added and 200 ml of each sample was loaded
onto one lane of a 1.5 mm thick 9% SDS-PAGE
discontinuous Laemmli gel and run at 25 V overnight.
The labeled bands were visualized by autoradiog-
raphy.
2.4. Receptor solubilization and WGA column chro-
matography
Approx. 2P108 S49 cells were collected by cen-
trifugation, washed twice in phosphate-buffered
saline, twice in 150 mM NaCl, 20 mM Tris-HCl, 5
mM EDTA, pH 7.4 then subjected to N cavitation in2
a Parr bomb. The disrupted cells were centrifuged at
200=g to remove intact cells and nuclei. The result-
ing supernatant was centrifuged at 35 000=g. The
membrane pellet was resuspended in a Dounce ho-
mogenizer at a protein concentration of 1.5 mgrml in
150 mM NaCl, 20 mM Tris-HCl, 5 mM EDTA, pH
 .  .7.4, 1.2% wrv digitonin, made from a 1.5% wrv
w xdigitonin solution prepared as described 21 . After
30 min incubation on ice, the suspension was again
centrifuged at 35 000=g and the supernatant re-
tained.
The protein content of the solubilized membrane
preparations was determined and equivalent amounts
 .of protein 0.4–1 mg were passed over columns
containing 1 ml immobilized WGA. The eluent was
passed over the columns two additional times to
maximize b -adrenergic receptor binding and the2
columns were subsequently washed with 7 ml digi-
tonin buffer 100 mM NaCl, 10 mM Tris-HCl, 5 mM
 . .EDTA, pH 7.4, 0.05% wrv digitonin . Bound re-
ceptor was eluted with 5 ml digitonin buffer contain-
ing 300 mM N-acetyl-D-glucosamine.
2.5. b -Adrenergic receptor inacti˝ation protocol2
A stock solution of BIM was prepared by diluting
20 mM BIM dissolved in 100% methanol to 10y5 M
in 100% ethanol. Cells, at a density of 5=105rml,
were treated with 10y8 M BIM. Following a 2-h
incubation at 378C, the cells were washed, under
sterile conditions, by three successive centrifugations
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in 100 ml growth medium at room temperature.
Following removal of the BIM, the cells were re-
turned to the incubator in normal growth medium.
Aliquots were withdrawn at intervals thereafter for
assessment of receptor density as described below.
2.6. b -Adrenergic receptor binding assay2
Measurement of b -adrenergic receptor was made2
w xusing intact S49 cells as described previously 19 .
Cells were harvested and washed twice in
phosphate-buffered saline prior to resuspension in
Dulbecco’s modified Eagle’s medium supplemented
 .with 0.1% wrv bovine serum albumin and 20 mM
Hepes, pH 7.4. Approx. 106 cells were incubated
 . w125 xwith y - I iodocyanopindolol for 1 h in a volume
of 0.25 ml at 378C in a shaking water bath. Measure-
ment of solubilized receptor was made in digitonin
buffer in a volume of 0.5 ml for 20 h at 4qC.
Non-specific binding was defined as that not com-
 .peted by addition of 1 mM " -propranolol. Mem-
branes were trapped on Whatman GFrC filter paper
using a Brandel cell harvester. Solubilized receptor
was trapped on the same filter paper pre-soaked in
 .10% wrv aq. polyethyleneimine.
2.7. Isolation of DNA
High molecular weight genomic DNA was isolated
from S49 cells by the method of Herrmann and
w x w xFrischauf 22 as described previously 19 .
2.8. PCR amplification of the b -adrenergic receptor2
The b -adrenergic receptor coding sequence was2
amplified in overlapping segments using the ther-
mostable DNA polymerase, Pfu. One of each primer
pair was synthesized with an artificial EcoRI recog-
 . Xnition site denoted in italics on its 5 -end to facili-
tate cloning; 5X1F GGAATTCGTAACAGCACT-
 . XTACGGTAGC y2115 to y2096 , 5 1R AGCACT-
 . XCATAAGTGACACCC y861 to y879 , 5 2F
 .TTACTGCCTTGTGCGGTTCT y1026 to y1006 ,
X 5 2R GGAATTCTTCCAGCTACCCTAGC y415 to
. Xy430 , 5 3F GGAATTCGGGTTGCACAGCAGC
 . Xy472 to y458 , 5 3R AGCAAGAAGTCGCT-
 .GTCGTT 16 to 35 , 1F GGAATTCACCTGCTAAC-
 . XCTGCCA y19 to y4 , 1F GGTGCGCTCACCT-
 .GCTAACCTGC y28 to y6 , 1R CAGAACTCG-
 .CACCAGAAGTT 307 to 326 , 2F CTGATCTAGT-
 .CATGGGCCTA 233 to 252 , 2R GGAATTCTGGT-
 .TAGTGTCCTGTCA 1305 to 1289 . Numbering of
the primers excludes the EcoRI sites and is based on
the sequence of the S49 b AR gene beginning at q12
with the A in the ATG start codon.
The PCR products were recovered by gel purifica-
tion on a 1% NuSieve agarose gel, recovered using
GELase, digested with EcoRI and cloned into
M13mp18 for sequencing. Bluerwhite selection was
applied to the M13 clones. Positive clones were
sequenced using the Sequenase II kit. The b -adren-2
ergic receptor fragments were sequenced using both
the Universal M13 y40 sequencing primer and se-
quence-specific primers.
2.9. Construction of the b -adrenergic receptor -2
pBluescript construct
The two overlapping PCR products encompassing
the entire b -adrenergic receptor coding sequence2
were recombined by PCR. Out of several strategies
that we employed, this proved to be the most success-
ful for recombining the coding sequence fragments.
0.1 ng of each fragment, amplified using the 1FX-1R
and 2F-2R primers, were purified on a NuSieve 1%
agarose gel, combined in a final volume of 100 ml
and subjected to a single round of PCR without
primers followed by an additional 24 cycles of PCR
in the presence of the 1FX and 2R primers. The
following temperature parameters were employed, 1
min 958C melt, 1 min 558C soak, 1 min 728C extend.
The terminal extension cycle was carried out for 5
min at 728C. The 1FX primer, which lacks the artifi-
cial EcoRI site present in primer 1F, was used both
to prevent primer dimer formation and to allow direc-
tional cloning. The S49 b -adrenergic receptor cod-2
ing sequence was ligated into pBluescript II SKq ,
the 5X-end into the SmaI site and the 3X-end into the
EcoRI site.
2.10. Quantitation
Protein was quantitated by the method of Peterson
w xusing bovine serum albumin as standard 23 . DNA
and RNA were quantitated by E .260
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3. Results and discussion
The two b -adrenergic receptor-deficient S49 cell2
p d w xvariants, b and b , were first reported in 1979 18 .
We have previously extended this observation by
demonstrating that the b p and b d variants also
express decreased receptor mRNA levels. The de-
creases in receptor mRNA levels in the variant cells
correlate with the decreases in receptor expression.
w xThere is no change in gene expression 19 .
To determine whether the decrease in receptor
mRNA level is also correlated with a decrease in the
rate of receptor synthesis, wild type and b d cells
were treated with a b -adrenergic receptor-specific2
 .alkylating agent, BIM Fig. 1 . Following removal of
the alkylating agent, the rate of receptor recovery was
measured. The initial rate of receptor recovery was
slowed in the b d cells vis-a-vis the rate observed`
with the wild type cells.
Other than a decrease in the number of receptors
and a corresponding decreased maximal ability of
agonists to promote altered cyclic AMP generation,
cellular regulation of cyclic AMP by both b -adren-2
ergic and PGE receptors expressed by the b p and1
d w xb variants cells appears to be normal 18 . How-
ever, to corroborate this conclusion from a biochemi-
cal standpoint, the receptors were radiolabeled in situ
w125 xusing I iodocyanopindololdiazirine, the photo-
Fig. 1. S49 b -adrenergic receptor recovery following receptor2
inactivation b -Adrenergic receptors on intact wild-type and b d2
S49 cells were inactivated by treatment with the irreversible
alkylating agent, BIM, as described in Section 2. The rate of
 . d  .receptor recovery, in both wild type B and b ’ S49 cells
was measured at intervals following washout of the BIM.
Fig. 2. Photoaffinity labeling of the S49 b -adrenergic receptor2
b -Adrenergic receptors on intact wild-type, b p and b d S492
w125 xcells were labeled with I iodocyanopindololdiazirine and the
membrane proteins were electrophoresed on SDS-PAGE. The
radiolabeled receptors were visualized by autoradiography.
w125 x w xaffinity analogue of I iodocyanopindolol 24 . Fol-
lowing UV-irradiation of the intact cells, a crude
membrane preparation that was essentially devoid of
nuclear material, was prepared. The labeled mem-
branes were electrophoresed on a discontinuous
SDS-PAGE system and the covalently radiolabeled
b -adrenergic receptors were visualized by auto-2
 .radiography Fig. 2 . Two radiolabeled bands were
seen with membranes prepared from wild-type S49
cells with molecular mass of 67 000 Da and 47 000
Da. The larger molecular mass band was the major
component; the smaller fragment was presumably a
product of proteolytic degradation. This pattern of
b -adrenergic receptor labeling is similar to that re-2
w xported previously in wild-type S49 cells 8 .
The labeling pattern observed with the receptor-de-
ficient variant cells was weaker than that obtained
with wild-type S49 cells, as expected due to the
lower receptor abundance in the variants. The charac-
teristic phenotype of the b p and b d S49 cells, that
w xof decreased b -adrenergic receptor expression 18 ,2
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w125 xFig. 3. Glycosidase sensitivity of the b -adrenergic receptor b -Adrenergic receptors on intact were labeled with I iodocyanopindo-2 2
loldiazirine and the membrane proteins were electrophoresed on SDS-PAGE following treatment with endoglycosidase H or endoglycosi-
dase F, as indicated. The radiolabeled receptors were visualized by autoradiography.
was confirmed several times throughout these studies
w125 xby I iodocyanopindolol binding, performed as de-
w xscribed previously 19 .
In addition to the decreased intensity of labeling
observed with the variant cells, we observed a shift of
the labeled bands toward smaller molecular mass,
60 000 and 42 000 Da in the variants vis-a-vis 67 000`
 .and 47 000 Da in the wild-type Fig. 2 . The degree
of this size shift was equivalent in the two variant
cells. One possible explanation for the decrease in
apparent molecular mass of the b -adrenergic is aber-2
rant receptor glycosylation since the mass of the core
protein is 47 000 Da based on its deduced amino acid
w xsequence 25 . Furthermore, glycosylation appears to
be unimportant for b -adrenergic receptor function in2
w xS49 cells 8 .
To determine whether altered glycosylation was
indeed responsible for the decreased molecular mass,
membranes prepared from photoaffinity labeled cells
were treated with endoglycosidase H and N-glyco-
sidase F prior to fractionation on SDS-PAGE Fig.
.3 . Treatment with endoglycosidase H was without
effect, but N-glycosidase F normalized the sizes of
the specifically radiolabeled species from the wild-
type, b p and b d S49 cells. A single but diffuse band
centered around 47 000 Da was observed following
N-glycosidase F treatment. These results are in ac-
cord with previous reports suggesting that the b -2
adrenergic receptor is glycosylated with complex
rather than high-mannose carbohydrate and that N-
glycosidase F, which cleaves complex carbohydrates,
has previously been shown to decrease the molecular
w xmass of the b -adrenergic receptor 26 .2
To test the hypothesis that the b p and b -adren-2
ergic receptor is glycosylated aberrantly, we mea-
Fig. 4. WGA binding of solubilized b -adrenergic receptors2
Crude membranes were prepared from S49 wild-type, b p and
b d S49 cells and solubilized with digitonin. The solubilized
material was passed repetitively over columns containing immo-
bilized WGA, the flow through and wash collected and termed
the ‘non-retained’ fraction. The bound material was eluted with
300 mM N-acetyl-D-glucosamine and this was termed the
‘sugar-eluted’ fraction. Protein and b -adrenergic receptor con-2
tent of each of the fraction was determined. Recovery of protein
and b -adrenergic receptor was equal to 88"6% and 104"13%2
 .ns6 respectively, and 9.4"3.2-fold receptor purification was
achieved in the sugar-eluted fractions. The asterisks indicate
achievement of statistically significant difference from wild type
 .by two-tailed T-test at the P -0.01 level ns2 .
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Fig. 5. The S49 wild-type b -adrenergic receptor sequence The nucleotide sequence of the S49 wild-type b -adrenergic receptor gene2 2
sequence is illustrated with the open reading frame denoted by upper case letters, whereas 5X and 3X non-coding sequence is denoted by
lower case letters. Numbering starts at q1 with the A in the ATG start codon. The locations of two single base differences between the
wild-type and variant cells’ sequences are noted by arrows. These correspond to loss of a T from a run of T centered around -1660 and
change of a T to G at position -1292 in both variants’ 5X non-coding sequence.
sured the ability of immobilized WGA to bind solubi-
lized b -adrenergic receptors from each of the three2
cells. Fig. 4 shows that immobilized WGA bound the
receptor solubilized from the wild type S49 cells
d significantly better than that from the b cells P-
.0.01, two-tailed T-test . Retention of the b -adren-2
ergic receptors solubilized from the b p cells was
intermediate between that from the wild type and b d
cells, although this difference failed to reach statisti-
cal significance. These results also suggest that the
b -adrenergic receptor on the b p and b d cells is not2
glycosylated normally.
George et al. reported that swainsonine, presum-
ably as a result of its inhibition of a-mannosidase II,
reduced the mobility of the S49 b -adrenergic recep-2
w xtor on SDS-PAGE 8 . We confirmed the previous
data that there was little or no effect F20% in our
.hands, data not shown of swainsonine treatment on
 . w125 xreceptor affinity for y - I iodocyanopindo-
loldiazirine and receptor number. In contrast, Cer-
vantes-Olivier et al. found that treatment of A431
human epidermoid carcinoma cells with either tuni-
camycin or monensin caused a redistribution of b -2
adrenergic receptors away from the cell surface to-
gether with a decreased cyclic AMP response to
w xisoproterenol 11 . These contrasting effects of glyco-
sylation inhibitors on the b -adrenergic receptor may2
be the result of other, more general, differences be-
tween the S49 and A431 cells.
Growing S49 cells in the presence of 0.2 mgrml
swainsonine for three days reduced the ability of
digitonin-solubilized b -adrenergic receptors to ad-2
here to immobilized WGA. Furthermore, growth of
the b p and b d variant cells in the presence of
swainsonine caused a greater inhibition of the ability
of the digitonin-solubilized b -adrenergic receptors2
to bind to immobilized WGA 66"1% and 70"1%
.inhibition, respectively than the receptor from the
 .wild type cells 44"3% inhibition in three experi-
ments. We conclude, therefore, that altered glycosyla-
tion of the b -adrenergic receptor occurs in the b p2
and b d variant cells and, furthermore, that this
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glycosylation defect must lie upstream of the removal
of mannose residues on the a arm of the high1-6
w xmannose structure 8 .
There are several possible explanations for aber-
rant glycosylation of the b -adrenergic receptor.2
These include N-terminal truncation of the receptor,
mutation of one or both of the two consensus glyco-
sylation sites or a malfunctioning glycosylation
mechanism. To determine whether the molecular ba-
sis for apparent alteration in b -adrenergic receptor2
glycosylation in the variant cells might lie within the
b -adrenergic receptor gene, we sequenced the entire2
coding region and the proximal two kilobases of the
5X non-coding region of the b -adrenergic receptor2
p d  .from the wild-type, b and b S49 cells Fig. 5 .
The murine b -adrenergic receptor gene, like that2
from all species thus far examined, is intronless and
the 5X flanking region contains transcription factor
binding sites, indicative of regulatory control of tran-
w xscription 2,25 . We were able to utilize PCR amplifi-
cation of genomic DNA. Genomic DNA was ampli-
fied by PCR using these primer pairs and the prod-
ucts were cloned into M13 mp18. The PCR products
thus cloned were sequenced and the sequences veri-
fied in at least two clones.
We found no differences in the coding region of
the b -adrenergic receptor gene from the wild-type2
 .and variant cells Fig. 5 . Thus, the decreased b -2
adrenergic receptor mass in the b p and b d cells is
not due to a change in the primary sequence of the
receptor in these cells. Lack of 5X truncation of the
receptor transcript as a possible cause is also ruled
unlikely by the fact that the size of the b -adrenergic2
receptor mRNA is equivalent in the wild-type, b p
d w xand b cells 19 .
In contrast to the lack of any sequence differences
noted in the open reading frame of the wild-type and
variant S49 cells’ b -adrenergic receptor gene se-2
quence, two single base mutations were noted in the
first two kilobases of the variant cells’ b -adrenergic2
receptor 5X non-coding sequence compared to that of
the wild-type. These were loss of a T from a run of
T, centered around y1660, and a T instead of a G at
position y1292 in both the variant cells. These
regions do not correspond to known regulatory sites
and we do not know whether they functionally impor-
tant in regulating receptor gene transcription. We
cannot rule out the possibility that these differences
may be the result of either PCR artifacts, allelic
differences or of random genetic drift that has taken
place in these cultured cells.
The entire S49 b -adrenergic receptor coding se-2
quence was reconstituted by performing PCR with
the 1FX and 2R primers on the two fragments that
together comprise the entire coding sequence. This
PCR-mediated ligation, or ‘jumping PCR’ as it has
w xalso been termed 27 offers a simple way to reassem-
ble larger DNA fragments from overlapping frag-
ments generated by PCR. The fragment correspond-
ing to the entire coding sequence was isolated on a
low-melting temperature agarose gel and cloned into
 .the EcoRI site in pBluescript SK q .
The sequence of the murine b -adrenergic receptor2
gene has been determined by two groups from ge-
w xnomic libraries of a C57BL mouse strain 3 and a
w x3T3-L1 mouse cell 25 . The S49 lymphoma cell line
was derived from a tumor induced in a Balbrc
w xmouse 28 . When the coding sequence of the S49
b -adrenergic receptor is aligned with that from the2
two other murine b -adrenergic receptor sequences2
reported, there is good accordance with only ten
nucleotide differences that result in a single inferred
amino acid change, His or Asp, at residue 21 Table
.1 . At least some of the sequence differences might
Table 1
Alignment of S49, C57 and 3T3 murine b -adrenergic receptors2
Nucleotide positions 61–63 280–285 760–762 1036–1044
S49 gac a tc ct t acg tc t tcg aaa
C57 cac a tc ct t agc tc t tcg aaa
3T3 gac acc tct acg tcc ttc gaa
Amino acid HisrAsp Ile Leu Ser Ser Ser Lys
Nucleotide sequences differences and the corresponding inferred amino acids are shown for three murine b -adrenergic receptors, those2
w x w xobtained from S49 cells, C57 3 and 3T3 25 mice.
( )R.J. Hughes et al.rBiochimica et Biophysica Acta 1356 1997 281–291290
be ascribed to sequencing errors. Where the sequence
of the S49 b -adrenergic receptor disagrees with one2
of the other two sequences, it agrees with the other.
The S49 sequence is, we believe, the consensus
sequence for the murine b -adrenergic receptor se-2
quence.
The decreased molecular mass of the b -adren-2
ergic receptor in the b p and b d variants is likely to
be the result of aberrant receptor glycosylation in
these cells. Thus, we are left with a paradox. How to
explain both decreased receptor expression and de-
creased receptor size in the b p and b d cells?
There is at least one precedent for altered glyco-
sylation causing altered expression of gene tran-
w xscripts; this is the insulin receptor 29 . Treatment of
lymphocytes with the glycosylation inhibitors 2-de-
oxyglucose or tunicamycin elicits a time-dependent
w xreduction of insulin receptor mRNA levels 29 . Some
transcription factors are known to be glycosylated
w x30,31 . It is conceivable that altered glycosylation,
while affecting neither the binding properties nor the
functional activity of the b -adrenergic receptor, af-2
 .fects the activity of a transcription factor s necessary
for gene transcription. Such a glycosylation defect
would have to be specific to the extent that it effects
 .the b -adrenergic receptor and factor s regulating2
b -adrenergic receptor mRNA expression.2
The prostaglandin E receptor is expressed nor-1
mally in the variant cells in terms of its ability to
w xstimulate cyclic AMP formation 18 . George et al.
w x8 show that treatment of cells with glycosidase
inhibitors elicits a decrease in the number of prosta-
glandin E receptors. Although PGE1 receptor ex-1
pression appears unaltered in the b p and b d vari-
ants, preventing glycosylation through the use of
inhibitors is likely to have a far greater impact on the
cells than the more specific glycosylation defect that
we believe we have uncovered. Our hypothesis is that
the glycosylation defect in the b p and b d variant
cells is specific in nature, its effect being directed
towards the b -adrenergic receptor and one or more2
transcription factors. Further studies will be necessary
to identify the precise glycosylation defect in these
S49 variant cells.
These results provide the first example of a de-
creased G-protein linked receptor expression that ap-
pears to be coincidental with altered receptor sensitiv-
ity to glycosidase, consistent with altered receptor
glycosylation. Both the decreased receptor expression
and impaired glycosylation result from a lesion out-
side of the receptor’s open reading frame. This obser-
vation is particularly intriguing in view of the fact
that other reports have demonstrated altered glyco-
sylation with no effect on b -adrenergic receptor2
w xexpression and function 8 . Decreased transcript ex-
pression coincident with impaired glycosylation may
turn out to be a phenomenon of regulatory signifi-
cance in other settings beside the expression of b -2
adrenergic and insulin receptors.
References
w x1 Dixon, R.A., Kobilka, B.K., Strader, D.J., Benovic, J.L.,
Dohlman, R.E., Frielle, T., Bolanowski, M.A., Bennet, C.D.,
 .Rands, E. and Diehl, R.E. 1986 Nature 321, 75–79.
w x2 Emorine, L.J., Marullo, S., Delavier, K.C., Kaveri, S.V.,
 .Durieu, T.O. and Strosberg, A.D. 1987 Proc. Natl. Acad.
Sci. USA 84, 6995–6999.
w x3 Allen, J.M., Baetge, E.E., Abrass, I.B. and Palmiter, R.D.
 .1988 Embo J. 7, 133–138.
w x  .4 Malbon, C.C. and Hadcock, J.R. 1988 Biochem. Biophys.
Res. Commun. 154, 676–681.
w x  .5 Applebury, M.C. and Hargrave, P.A. 1987 Vision Res. 26,
1881–1895.
w x6 Dohlman, H.G., Bouvier, M., Benovic, J.L., Caron, M.G.
 .and Lefkowitz, R.J. 1987 J. Biol. Chem. 262, 14282–
14288.
w x7 Caron, M.G., Kobilka, B.K., Frielle, T., Bolanowski, M.A.,
 .Benovic, J.L. and Lefkowitz, R.J. 1988 J. Recept. Res. 8,
7–21.
w x  .8 George, S.T., Ruoho, A.E. and Malbon, C.C. 1986 J. Biol.
Chem. 261, 16559–16564.
w x  .9 Severne, Y., Jurss, R. and Vauquelin, G. 1986 Biochem.
Pharmacol. 35, 4375–4380.
w x  .10 Lautens, L.L. and Ruoho, A.E. 1987 Brain. Res. 426,
401–406.
w x11 Cervantes, O.P., Delavier, K.C., Durieu, T.O., Kaveri, S.,
 .Desmandril, M. and Strosberg, A.D. 1988 Biochem. J.
250, 133-43.
w x12 Hausdorff, W.P., Bouvier, M., O’Dowd, B.F., Irons, G.P.,
 .Caron, M.G. and Lefkowitz, R.J. 1989 J. Biol. Chem. 264,
12657–12665.
w x13 Hausdorff, W.P., Hnatowich, M., O’Dowd, B.F., Caron,
 .M.G. and Lefkowitz, R.J. 1990 J. Biol. Chem. 265, 1388–
1393.
w x14 Raymond, J.R., Hnatowich, M., Lefkowitz, R.J. and Caron,
 .M.G. 1990 Hypertension 15, 119–131.
w x  .15 Lefkowitz, R.J. and Caron, M.G. 1990 Adv. Second.
Messenger Phosphoprot. Res. 24, 1–8.
w x16 Coffino, P., Bourne, H.R., Insel, P.A., Melmon, K.L., John-
 .son, G. and Vigne, J. 1978 In Vitro 14, 140–145.
( )R.J. Hughes et al.rBiochimica et Biophysica Acta 1356 1997 281–291 291
w x  .17 Insel, P.A. 1981 in Cell Regulation by Intracelluler Signals
 .Swillens, S. and Dumont, J., eds. , pp. 137–145, Plenum
Press, New York.
w x18 Johnson, G.L., Bourne, H.R., Gleason, M.K., Coffino, P.,
 .Insel, P.A. and Melmon, K.L. 1979 Mol. Pharmacol. 15,
16–27.
w x19 Hughes, R.J., Howard, M.J., Allen, J.M. and Insel, P.A.
 .1991 Mol. Pharmacol. 40, 974–979.
w x20 Terman, B.I., Reece, J.F., Brown, R.D. and Insel, P.A.
 .1988 Biochem. J. 253, 363–370.
w x  .21 Shorr, R.G., Lefkowitz, R.J. and Caron, M.G. 1981 J.
Biol. Chem. 256, 5820–5826.
w x  .22 Herrmann, B.G. and Frischauff, A.-M. 1987 Methods En-
zymol. 152, 180–183.
w x  .23 Peterson, G.L. 1977 Anal. Biochem. 83, 346–356.
w x24 Wong, S.K., Slaughter, C., Ruoho, A.E. and Ross, E.M.
 .1988 J. Biol. Chem. 263, 7925–7928.
w x25 Nakada, M.T., Haskell, K.M., Ecker, D.J., Stadel, J.M. and
 .Crooke, S.T. 1989 Biochem. J. 260, 53–59.
w x26 Benovic, J.L., Staniszewski, C., Cerione, R.A., Codina, J.,
 .Lefkowitz, R.J. and Caron, M.G. 1987 J. Recept. Res. 7,
257–281.
w x  .27 Hoss, M., Handt, O. and Paabo, S. 1994 in The Poly-¨ ¨¨
merase Chain Reaction Mullis, K., Ferre, F. and Gibbs,´
.R.A., eds. , pp. 257–264, Birkhauser, Boston.¨
w x  .28 Horibata, K. and Harris, A.W. 1970 Exp. Cell Res. 60,
61–70.
w x  .29 Briata, P., Briata, L. and Gherzi, R. 1990 Biochem. Bio-
phys. Res. Commun. 169, 397–405.
w x  .30 Jackson, S.P. and Tjian, R. 1989 Proc. Natl. Acad. Sci.
USA 86, 1781–1785.
w x  .31 Jackson, S.P. and Tjian, R. 1988 Cell 55, 125–133.
